IZOZF - Izotropic Engages Investor Relations and Market Awareness Consultants
(TheNewswire)
V ancouver , BC - TheNewswire - November 2, 2020 - Izotropic Corporation (" Izotropic " or the " Company ") (CSE: IZO ) (C NSX : IZO. CN ) (US: IZOZF )(FSE: 1R3 ) is pleased to announce that it has entered into thefollowing consulting agreements to broaden its market presence andinvestor base and to provide investor relations services for itsshareholders:
Doug McKay and Associates has beenengaged for a period of 12 months for a fee of $108,000.00. 300,000stock options have been granted at an exercise price of $1.32. Thestock option is in effect for two (2) years and vests immediately.
Mr. Dan Sammartino has been engaged as a dedicatedinvestor and shareholder communications specialist. The initialagreement term is for twelve (12) months with a monthly fee of$5,000.00 and is subject to renewal. 200,000 stock options have beengranted at an exercise price of $1.32. The stock option is in effectfor two (2) years and vests immediately.
The Company has also granted an additional 200,000stock options to third party consultants at an exercise price of$1.32. The stock options are in effect for two (2) years and vestimmediately.
For Investor relations inquiries,please contact Dan Sammartino at 1-778-962-0234.
ON BEHALF OF THE BOARD
Robert Thast
Chief Executive Officer
Investor Relations: 1-778-962-0234
Email: info@izocorp.com
Website: izocorp.com
About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S.operating subsidiary, Izotropic Imaging Corp. have been established tocommercialize the next generation of breast imaging technology forearly diagnosis of breast cancer. The Izotropic Breast CT ImagingSystem produces high resolution breast images in 3D. A single 10second breast CT scan acquires approximately 500 images, withoutpainful breast compression, providing radiologists with fully 3Dviewing of the scanned breast. Mammography scanning requirescompression of the breast between 2 imaging plates, resulting in 2Dimages.
The Company has the exclusive worldwide license fromthe University of California, Davis to commercialize the technologydeveloped by principal founder and Company director Dr. John M. Booneand researchers at UC Davis. The license includes all intellectualproperty, trade secrets, patents and patent-pending applications thatare the foundation of the Company's breast CT imaging platform.
Approximately $20 million in research funding and over15 years of research and development have been invested in developingthis groundbreaking breast CT imaging technology. Research includes acurrent, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology willbe a disruptive entry to the market, overcoming many of the challengesfaced by existing breast imaging modalities.
Forward Looking Statements
This document may contain forward-looking statementsthat are based on the Company's expectations, estimates andprojections regarding its business and the economic environment inwhich it operates. These statements are not guarantees of future performance and involve risks anduncertainties that are difficult to control or predict. Therefore,actual outcomes and results may differ materially from those expressedin these forward-looking statements and readers should not place unduereliance on such statements. Statements speak only as of the date onwhich they are made and the Company undertakes no obligation to updatethem publicly to reflect new information or the occurrence of futureevents or circumstances, unless otherwise required to do so bylaw.
Copyright (c) 2020 TheNewswire - All rights reserved.